CRISPR Therapeutics CRSP Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$122.93M+5.9% | -$130.61M-22.7% | -$106.44M+49.0% | -$208.55M-53.3% | -$136M-264% | ||
| $4.32M-23.7% | $5.66M+27.7% | $4.43M-4.6% | $4.65M-1.8% | $4.74M-2.2% | ||
| $16.32M-9.7% | $18.08M+8.9% | $16.6M-5.7% | $17.61M-12.9% | $20.21M-7.9% | ||
| -$108.9M-17.7% | -$92.55M-9.4% | -$84.63M+25.7% | -$113.88M-111% | -$53.95M-7.8% | ||
| $504K-2.5% | $517K+599% | $74K-36.8% | $117K-43.2% | $206K-18.9% | ||
| -$410.74M— | —— | -$119.23M-270% | $69.98M+454% | -$19.76M— | ||
| $591.91M+408% | $116.41M-60.8% | $296.77M+13,043% | $2.26M-78.7% | $10.59M-37.3% | ||
| $72.24M+18.3% | $61.06M-34.3% | $92.88M+323% | -$41.57M+34.1% | -$63.07M— | ||
| -$109.4M-17.5% | -$93.07M-9.9% | -$84.71M+25.7% | -$114M-111% | -$54.15M-7.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does CRISPR Therapeutics's cash flow data come from?
- Every line is extracted from CRISPR Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.